Assessing effectiveness of adding topical atorvastatin 1% ointment to topical calcineurin inhibitor treatment for nonsegmental vitiligo patients visited at Afzalipour hospital dermatology clinics

Kerman University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新: 2020年9月7日

试验速览

暂无简介。

•A diagnosis of non-segmental vitiligo made by the attending dermatologist who first visits patient at the Afzalipour Hospital's dermatology clinic
•Filling out and signing the written informed consent form by the patient
•Patient's age of at least 18 years at the time of signing the informed consent
•Male or nonpregnant and nonbreastfeeding female

•Any dermatologic disorder other than vitiligo; infectious disorders; inflammatory disorders; diabetes mellitus; cardiovascular disorders; renal disorders; liver disorders; endocrinologic disorders; autoimmune disorders; any other uncompensated medical disorder
•A diagnosis of segmental vitiligo made by the attending dermatologist who initially visits patient
•Pregnancy or breastfeeding
•History of hypersensitivity to atorvastatin
•Using any type of drugs of statin group during the 8 week period immediatly before starting the trial
•Using systemic immunosuppressive or immunomodulator treatments (cyclosporin A, corticosteroids) during the 4 week period immediatly before starting the trial or using azathioprine, methotrexate, mycophenolate mofetil, or janus kinase inhibitors during the 8 week period immediatly before starting the trial
•Phototherapy as a treatment of vitiligo or any other disorder during the 4 week period immediatly before starting the trial
•Alcohol or illicit drug use
•History of dermatologic malignancy during the 5 year period immediatly before starting the trial or current dermatologic malignancy
•Being involved in any other clinical trial
•Noncompliant patient

发起方